Military Veterans Are Dying From Opioids at Rates the VA Cannot Explain

Medically Reviewed by Rab Nawaz Khan, M.D

Somewhere inside the machinery of American health policy, two lines on a chart are moving in opposite directions, and the official story struggles to hold them both.

The first line falls. After the Department of Veterans Affairs launched its Opioid Safety Initiative in 2013, prescriptions for opioid painkillers inside the system dropped sharply and kept dropping. Fewer high doses. Fewer long-term prescriptions. Fewer of the pill combinations that clinicians had come to see as dangerous. By almost any measure the VA set for itself, the effort worked.

The second line rises. Over the same years, veterans kept dying of opioid overdose at rates that climbed rather than fell. The safest reading of the data is uncomfortable: the intervention did what it was designed to do, and the dying did not stop. When a public health strategy delivers on its stated goal while the outcome it was meant to improve moves the wrong way, you are left with a paradox that no press release resolves cleanly. That gap between what the VA changed and what actually happened is the reason people say the agency cannot explain these deaths.

The phrase is only half true, and understanding which half matters more than any single statistic.

The Number That Was Supposed to Go Down

For most of the 2000s, prescribing was treated as the throttle on the overdose crisis. Give out fewer opioids, the thinking went, and fewer people would become dependent, misuse them, and die. It was a reasonable theory, and the early evidence behind it was real. Higher prescribed doses were associated with a higher risk of fatal overdose, a link established in veteran populations by research that helped shape national policy.

So the VA moved. Academic detailing reached providers. Dose ceilings and tapering guidance spread through the system. Naloxone distribution expanded. The prescribing curve bent downward faster inside the VA than in most of American medicine. If the prescription-centered model of the crisis had been complete, veteran overdose deaths should have followed the pills down.

They did not.

The Number That Went Up Instead

Researchers linking VA records to national death data found that the opioid overdose rate among Veterans Health Administration patients rose from 14.47 per 100,000 in 2010 to 21.08 per 100,000 in 2016, an increase of roughly two-thirds after adjusting for the population’s changing age and makeup. A broader look across the veteran population found drug overdose mortality climbing about 53 percent between 2010 and 2019. However you slice the cohort, the direction was up.

The most revealing detail sits inside those deaths. When investigators examined the VA prescription histories of veterans who died of opioid overdose, they uncovered something that quietly dismantles the prescription-first framework. As documented in a 2019 study of Veterans Health Administration deaths, the share of overdose victims who had actually received a VA opioid prescription in the months before dying dropped substantially over time. By 2016, only a minority of veterans who died of an opioid overdose had a recent VA opioid analgesic in hand. The rise was driven not by the pills the VA was cutting, but by heroin and by synthetic opioids such as fentanyl, often taken in combination.

In other words, the system got very good at controlling the one variable it could measure and reach, and the deaths migrated to variables it could not.

What the VA Can and Cannot See

Here is the structural fact that most explanations skip. The Veterans Health Administration is the largest integrated health system in the country, but it treats only a slice of the people who served. In recent years, roughly a third of American veterans have used VA health care in a given year. The majority are somewhere else, seen by community doctors, covered by private insurance or Medicare, or not in regular care at all.

That matters enormously for a mortality puzzle, because the VA’s instruments are calibrated to its own patients. Its prescribing data, its naloxone programs, its risk models, and its safety initiatives all operate on the population inside the building. When a National Academies examination of veteran suicide risk noted that the largest count of veteran suicides occurs among those not currently in VA care, it pointed at the same blind spot that shadows the overdose numbers. The deaths concentrate precisely where the agency’s visibility and leverage run out.

For years the problem was literal. The VA was slow to connect to state prescription drug monitoring programs, launching a nationwide interface only in 2021, which meant that for a long stretch its clinicians could not easily see what other prescribers were giving the same patient. A veteran could be tapered inside the VA and topped up elsewhere, and the record that should have caught it was split down the middle. The agency was trying to manage a whole person while holding half the chart.

An organization cannot fully explain deaths it was never built to observe. That is not the same as the deaths being unexplainable.

The Tapering Paradox

The harder part of the story is that some of the VA’s most well-intentioned safety measures carried risks of their own, and the evidence for this comes largely from the VA’s own data.

In a large 2020 analysis of VA patients published in The BMJ, researchers found that stopping opioid treatment was associated with an increased risk of death from overdose or suicide, and that the risk grew the longer a patient had been on opioids before the medication was stopped. The danger was highest in the period right after discontinuation. A separate 2021 study in JAMA reached a parallel conclusion about dose reduction, reporting that tapering long-term opioid patients was associated with higher rates of overdose and mental health crisis compared with staying the course.

Read together, these findings describe a genuine clinical bind rather than a villain. A patient held on high-dose opioids faces one set of risks. The same patient, abruptly cut off or tapered too fast, can face another, including withdrawal, uncontrolled pain, despair, and in too many cases a turn toward whatever the illicit market offers. Clinicians were told to reduce prescribing to save lives, and in some individual cases the reduction itself became a moment of acute danger. This is the kind of second-order effect that a purely prescription-focused strategy was not designed to anticipate, and it is a large part of why the aggregate numbers refused to cooperate.

Fentanyl Changed the Question

While the VA was refighting the last war, the drug supply moved on. Since about 2013, the country has been living through what the Centers for Disease Control and Prevention describes as the third wave of the overdose crisis, dominated not by prescription pills but by illicitly manufactured fentanyl and its analogs. These synthetic opioids now saturate the street supply, are pressed into counterfeit pills, and are mixed into heroin, cocaine, and methamphetamine, frequently without the user’s knowledge. By 2023, according to national overdose statistics compiled by the National Institute on Drug Abuse, synthetic opioids were involved in roughly seven of every ten overdose deaths in the United States.

Against a supply that potent and that unpredictable, the lever the VA was pulling simply does not reach the mechanism doing the killing. A veteran who never held a VA prescription, who buys a pill on the assumption that it is oxycodone and receives a fatal dose of fentanyl instead, does not show up as a prescribing problem in anyone’s dashboard. The agency can measure and control what it dispenses. It cannot measure or control the counterfeit tablet passed hand to hand three counties away.

Why “Cannot Explain” Is Only Half True

Put the pieces together and the mystery thins considerably.

Veteran overdose deaths rose while VA prescribing fell because the deaths were never mostly about VA prescribing in the first place. They were about a population the agency only partly sees, a drug supply it does not touch, chronic pain and psychological injury that outlast any prescription, and, in a painful subset of cases, the very tapering meant to protect people. A biopsychosocial reading of the crisis, laid out in a 2022 review in Annals of Medicine, argues that overdose risk among veterans emerges from the interaction of biological, psychological, and social forces set in motion before, during, and after service. Reduce that to a prescription count and you will misread the whole thing, which is roughly what happened.

So what remains genuinely unexplained is narrower than the headline suggests, but it is real. The VA cannot fully account for deaths among veterans it never treats, because the surveillance systems that would let it do so are still being stitched together across federal and state lines. It cannot always say why one tapered patient stabilizes and another does not. And it cannot, from prescribing data alone, predict how the illicit market will mutate next. The agency’s official model was built for a version of the crisis that has already passed, and rebuilding the instruments to match the present is slow work.

There is a flicker of better news in the aggregate. National overdose deaths appear to have peaked around 2022 and then fell, with a sharp decline through 2024 that public health analysts attribute partly to fentanyl market changes and wider naloxone access. The VA’s own annual reporting, including the veteran suicide data the agency publishes each year, is where the veteran-specific version of that trend will eventually be judged. A falling national curve is worth noting, but it does not by itself close the gap this article is about.

What Actually Helps

If the diagnosis is that the crisis outgrew a prescription-only response, the treatment follows from it, and here the evidence is comparatively settled.

Medications for opioid use disorder, including buprenorphine and methadone, reduce overdose deaths and all-cause mortality, and expanding access to them is among the most reliable interventions available. Naloxone in the hands of veterans and the people around them prevents fatal overdoses in real time. Low-barrier, wraparound services reach the isolated and the reluctant, including the large share of veterans who never walk into a VA clinic. And on the clinical side, the lesson of the tapering research is not to abandon opioid stewardship but to practice it without abandoning the patient, weighing the risks of continuing and the risks of stopping as two real hazards rather than one.

None of that is a slogan about pill counts. It is slower, more individual, and harder to graph. It is also the only version of the response that matches the crisis as it actually exists rather than the one the VA set out to solve a decade ago. The deaths were never as inexplicable as they looked. They were being measured with the wrong ruler.

If You or a Veteran You Know Is Struggling

This article discusses overdose and suicide, which can be difficult subjects. If you are a veteran in crisis or worried about one, the Veterans Crisis Line is available at any hour by dialing 988 and then pressing 1, or by texting 838255. For substance use support, the SAMHSA National Helpline can be reached at 1-800-662-4357. Help is confidential and free.

Disclaimer

This article is provided for general informational and educational purposes only and does not constitute medical, psychological, or legal advice. It is not a substitute for professional diagnosis, treatment, or the guidance of a qualified healthcare provider. Opioid dependence, chronic pain management, and opioid tapering are complex clinical matters that must be handled by licensed professionals who know the individual patient. Never start, stop, or change the dose of any prescribed medication, including opioids, without consulting your prescriber, as abrupt discontinuation can carry serious risks. The statistics and study findings summarized here reflect the sources cited at the time of writing and may be updated by subsequent research. If you or someone you know may be experiencing a medical emergency or overdose, call your local emergency number immediately.

References

1. Lin LA, Peltzman T, McCarthy JF, Oliva EM, Trafton JA, Bohnert ASB. Changing trends in opioid overdose deaths and prescription opioid receipt among veterans. American Journal of Preventive Medicine. 2019;57(1):106-110. doi:10.1016/j.amepre.2019.01.016
2. Oliva EM, Bowe T, Manhapra A, Kertesz S, Hah JM, Henderson P, Robinson A, Paik M, Sandbrink F, Gordon AJ, Trafton JA. Associations between stopping prescriptions for opioids, length of opioid treatment, and overdose or suicide deaths in US veterans: observational evaluation. BMJ. 2020;368:m283. doi:10.1136/bmj.m283
3. Agnoli A, Xing G, Tancredi DJ, Magnan E, Jerant A, Fenton JJ. Association of dose tapering with overdose or mental health crisis among patients prescribed long-term opioids. JAMA. 2021;326(5):411-419. doi:10.1001/jama.2021.11013
4. Bohnert ASB, Valenstein M, Bair MJ, Ganoczy D, McCarthy JF, Ilgen MA, Blow FC. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA. 2011;305(13):1315-1321. doi:10.1001/jama.2011.370
5. Bennett AS, Guarino H, Britton PC, O’Brien-Mazza D, Cook SH, Taveras F, Cortez J, Elliott L. U.S. military veterans and the opioid overdose crisis: a review of risk factors and prevention efforts. Annals of Medicine. 2022;54(1):1826-1838. doi:10.1080/07853890.2022.2092896
6. Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC Clinical Practice Guideline for Prescribing Opioids for Pain, United States, 2022. MMWR Recommendations and Reports. 2022;71(3):1-95. doi:10.15585/mmwr.rr7103a1
7. Centers for Disease Control and Prevention. Understanding the Opioid Overdose Epidemic. National Center for Injury Prevention and Control. Updated 2025. Available at: https://www.cdc.gov/overdose-prevention/about/understanding-the-opioid-overdose-epidemic.html
8. National Institute on Drug Abuse. Drug Overdose Death Rates. Updated 2025. Available at: https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates
9. National Academies of Sciences, Engineering, and Medicine. Identifying and Managing Veteran Suicide Risk: Best Practices, Gaps, and Challenges. Washington, DC: National Academies Press; 2023. Available at: https://www.ncbi.nlm.nih.gov/books/NBK596467/
10. U.S. Department of Veterans Affairs, Office of Mental Health and Suicide Prevention. National Veteran Suicide Prevention Annual Report (2023 data). 2025. Available at: https://news.va.gov/145131/va-veteran-suicide-prevention-report-2023-data/